Editor’s Letter
Latest features in GaBI Journal, 2017, Issue 3
It is clear that greater use of generics and biosimilars could greatly decrease healthcare costs and thereby increase availability of important medicines. It is equally clear that these potential savings… Read More »
What to look forward to in GaBI Journal, 2017, Issue 2
The use both generics and biosimilars offers the potential to increase availability of medicines through decreases in cost that should occur when an expensive product (drug) loses patent protection and… Read More »
Editor’s introduction to the initial issue of the sixth volume of GaBI Journal
This first issue of 2017 includes a range of manuscripts of interest to readers. A Letter to the Editor from Professor Mohamed Izham Mohamed Ibrahim and Nada Moustafa Abdel Rida… Read More »
Fourth and final issue of GaBI Journal’s fifth volume
This fourth and final GaBI Journal issue of 2016 begins with the paper by Adjunct Professor Pekka Kurki about ‘applying ancient principles in a modern society’ in which he discusses… Read More »
Latest features in GaBI Journal, 2016, Issue 3
The informed, appropriate use of follow-on pharmacological agents can provide significant cost savings for patients and payers. These savings can then be used by governments and patients to increase access… Read More »
What to look forward to in GaBI Journal, 2016, Issue 2
This second issue of 2016 includes manuscripts that cover a number of important issues of interest to GaBI Journal including methods used to assess bioequivalence and decide on interchangeability, patient and… Read More »
Editor’s introduction to the initial issue of the fifth volume of GaBI Journal
This issue begins with a Letter to the Editor by Professor Fabio V Teixeira from the Brazilian Inflammatory Bowel Disease (IBD) Society that deals basically with the issue of extrapolation… Read More »
Fourth and final issue of GaBI Journal’s fourth volume
This last issue of 2015 starts with a Commentary by Drs Christoph Baumgärtel and Brian Godman concerning the approval of generic versions of narrow therapeutic margin products; including immunosuppressant drugs.… Read More »
Latest features in GaBI Journal, 2015, Issue 3
This issue of the journal contains a number of manuscripts that discuss proposals to simplify the evaluation of, and therefore decrease the cost of developing, follow-on biological products. These controversial… Read More »
What to look forward to in GaBI Journal, 2015, Issue 2
This entire issue of the GaBI Journal could be titled ‘World News’ since it contains manuscripts describing global generics and biosimilar activities. The Commentary by Leng et al. describes regulatory… Read More »